Proteomic approaches to validate novel cardiac biomarkers for myocardial infarcti

验证心肌梗塞新型心脏生物标志物的蛋白质组学方法

• 批准号: 8891482
• 负责人: Sakthivel Sadayappan
• 金额: $ 9.17万
• 依托单位: LOYOLA UNIVERSITY CHICAGO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8891482
• 关键词: Amino Acid Sequence; Amino Acids; Animal Model; Animals; Appearance; Binding Proteins; Biological Assay; Biological Markers; Blood; Cardiac; Cardiac Myocytes; Cardiac Myosins; Cardiovascular system; Caring; Cleaved cell; Creatine Kinase; Data; Development; Diagnosis; Diagnostic; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Genes; Goals; Gold; Half-Life; Heart; Heart failure; Human; Ischemia; Isotonic Exercise; Kinetics; Label; Laboratories; Liquid Chromatography; Mass Spectrum Analysis; Measurable; Measures; Methods; Microfilaments; Molecular; Monitor; Mus; Mutation; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myoglobin; N-terminal; Pathogenesis; Patients; Peptides; Phosphorylation; Pilot Projects; Plasma; Protein C; Protein Dephosphorylation; Proteins; Proteolysis; Proteomics; Reaction; Reperfusion Injury; Reperfusion Therapy; Resistance; Role; Sampling; Sarcomeres; Signal Transduction; Specificity; Staging; Structure; Testing; Thick Filament; Thin Filament; Troponin I; base; bone; diagnostic assay; early onset; genetic regulatory protein; injured; myosin-binding protein C; novel; tandem mass spectrometry; time use; verification and validation

DESCRIPTION (provided by applicant): Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) regulates sarcomeric structure, as well as myocardial contractility, and confers cardioprotection. My long-term goal is to define the role(s) of cMyBP-C phosphorylation in contractile function in order to understand the molecular mechanisms that underlie cardioprotection. We recently showed that (1) cMyBP-C is an easily releasable and soluble myofilament, (2) dephosphorylation of cMyBP-C results in its degradation and (3) release into the blood post-myocardial infarction (MI) and (4) its N'-fragments appear within 30 minutes of ischemia-reperfusion injury. In addition, we showed that plasma cMyBP-C levels are significantly increased in animal models and patients with MI. Strikingly, the level of plasma cMyBP-C is significantly higher than the gold standard plasma cardiac troponin I (2.0-fold molar). However, verification and validation of the precise amount of plasma cMyBP-C is the next critical step. Therefore, using selective and specific proteomic approaches, the short-term goal is to develop an assay that precisely quantitates the levels of plasma cMyBP-C. My central hypothesis is that cMyBP-C is a bone fide early, selective and measurable cardiac-specific biomarker, which appears within 30 minutes of ischemia. Thus, the overall objectives of the proposal are as follows: determine a cMyBP-C-specific amino acid region in order to develop a selective proteomics-based assay using the liquid chromatography-tandem-mass spectrometry (LC-MS-MS) and selective reaction monitoring (SRM) approaches (Specific Aim 1); verify the accuracy of the SRM approach for quantifying plasma cMyBP-C levels in both animal and human plasma samples (Specific Aim 2); and cross-validate the SRM assay with the conventional sandwich ELISA assay (Specific Aim 3). Plasma samples taken from ischemia- reperfusion-injured mice and patients with MI will be used in these analyses, compared to naive and sham operated mice and normal healthy controls. Validating the proteomic approaches will result in an assay that can accurately measure the level of cMyBP-C in the circulatory system, as well as define its presence as an early-released, cardiac-specific and selective marker of early-onset MI.

描述（由申请人提供）：心肌肌球蛋白结合蛋白-C (cMyBP-C) 的磷酸化调节肌节结构以及心肌收缩力，并赋予心脏保护作用。我的长期目标是确定 cMyBP-C 磷酸化在收缩功能中的作用，以便了解心脏保护的分子机制。我们最近表明，(1) cMyBP-C 是一种易于释放且可溶的肌丝，(2) cMyBP-C 的去磷酸化导致其降解，(3) 心肌梗塞 (MI) 后释放到血液中，(4) 它的 N' 片段在缺血再灌注损伤后 30 分钟内出现。此外，我们发现动物模型和 MI 患者的血浆 cMyBP-C 水平显着升高。引人注目的是，血浆 cMyBP-C 的水平显着高于金标准血浆心肌肌钙蛋白 I（2.0 倍摩尔）。然而，验证和确认血浆 cMyBP-C 的精确量是下一个关键步骤。因此，使用选择性和特异性蛋白质组学方法，短期目标是开发一种精确定量血浆 cMyBP-C 水平的测定方法。我的中心假设是，cMyBP-C 是一种真正的早期、选择性和可测量的心脏特异性生物标志物，它在缺血后 30 分钟内出现。因此，该提案的总体目标如下：确定 cMyBP-C 特异性氨基酸区域，以便使用液相色谱-串联质谱 (LC-MS-MS) 和选择性反应监测 (SRM) 方法开发基于选择性蛋白质组学的测定（具体目标 1）；验证 SRM 方法定量动物和人类血浆样本中血浆 cMyBP-C 水平的准确性（具体目标 2）；并将 SRM 测定与传统夹心 ELISA 测定进行交叉验证（具体目标 3）。取自缺血再灌注损伤小鼠和心肌梗死患者的血浆样本将用于这些分析，并与未经处理和假手术的小鼠以及正常健康对照进行比较。验证蛋白质组学方法将产生一种能够准确测量循环系统中 cMyBP-C 水平的检测方法，并将其定义为早发性 MI 的早期释放、心脏特异性和选择性标记物。